The UK’s National Institute for Health and Care Excellence (NICE) has sent a request to Eli Lilly asking for more data regarding Mounjaro (tirzepatide) before it will cover it for NHS patients. The decision comes based on data comparing the drug’s efficacy to Novo Nordisk’s rival drug Ozempic and standard insulin therapy. While the data showed Mounjaro was more effective at weight loss and glucose control, NICE needs more information before making a coverage decision.
According to Fraiser Kansteiner, “Now, NICE is asking Lilly to fork over more data to address uncertainties around its clinical data when compared to ‘all relevant alternative treatments.’ Likewise, Lilly must submit ‘further analyses and clarifications’ on its provided economic model for the drug. According to the cost watchdog, Lilly’s economic model for tirzepatide couldn’t be ‘fully [scrutinized]’ by NICE’s external assessment group. Further, Lilly failed to provide evidence showing how the model results compare with other economic models for diabetes.”
To read more, click here.
(Source: Fierce Pharma, June 27th, 2023)